RARE NASDAQ
Ultragenyx Pharmaceutical Inc.
1W: +5.0%
1M: -42.6%
3M: -54.8%
YTD: -35.5%
1Y: -49.2%
3Y: -58.8%
5Y: -84.0%
$15.22
+0.47 (+3.19%)
Weekly Expected Move ±9.7%
$12
$14
$15
$17
$18
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts
Bank of America Corp DE Invests $38.35 Million in Ultragenyx Pharmaceutical Inc. $RARE
Ultragenyx Pharmaceutical (NASDAQ:RARE) Sees Unusually-High Trading Volume on Analyst Upgrade
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy
Ultragenyx (RARE) Surges 12.6%: Is This an Indication of Further Gains?
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
Ultragenyx wins FDA approval for pediatric gene therapy for Sanfilippo syndrome
Why This Biotech Stock Just Got a Rare Double Upgrade - Barron's
RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares - Yahoo Finance
RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares
RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears — Failed Angelman Syndrome Trial Weighs On Shares - Stocktwits
Theodore Alan Huizenga Sells 1,283 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat
Cameco vs. USA Rare Earth: Which Renewable Energy Stock Is a Better Buy in 2026? - The Motley Fool
Ultragenyx (NASDAQ: RARE) executive plans $17K stock sale - Stock Titan
Should You Ignore MP Materials and Buy This Rare-Earth Stock Instead? - Yahoo Finance
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up – What’s Next?
Ultragenyx Pharmaceutical Inc. $RARE Stake Reduced by AXQ Capital LP
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout
Ultragenyx Pharmaceutical Sees Unusually Large Options Volume (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $59.44 Average PT from Brokerages
Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback - Yahoo Finance
Rare Stock Picks In August 2026 - From 21 Discerning Analysts - Seeking Alpha
IONS Edges Up After-Hours On FDA’s Green Light For Neurology Drug After Being Dragged Down By Ultragenyx’s Failed Trial
Ultragenyx's 'Fall From Grace' — Shares Crash 44%, Hitting A Record Low
Nvidia, Tesla, Robinhood, Snowflake, Ultragenyx, Ciena, and More Stocks That Explain Today’s Market
Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 44% Drop.
Ultragenyx slides amid multiple downgrades on trial setback for Angelman syndrome drug
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals
Ultragenyx mulls fate of rare disease programme on Phase III flop
Ultragenyx Shares Drop Following Failed Phase III Clinical Trial - Pharmaceutical Executive
Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More
At a glance: stocks gapping down premarket
Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study
RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades – This Analyst Sees Another Problem Ahead
Why Did NIO, RARE, MCD Stocks Fall To 52-Week Lows? - Yahoo Finance
RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades – This Analyst Sees Another Problem Ahead - TradingView
Ultragenyx drops on Phase 3 trial failure for Angelman syndrome drug
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
164,813 Shares in Ultragenyx Pharmaceutical Inc. $RARE Bought by Deutsche Bank AG
$RARE Ultragenyx Pharma INC,FDA APPROVAL
Biggest stock movers Thursday: Crypto stocks, WMT, BABA, DE, and more
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos - Yahoo Finance
Ultragenyx wins accelerated approval of gene therapy for glycogen storage disease
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Ultragenyx (RARE) Q2 2026 Earnings Call Transcript
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up Following Strong Earnings
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx Pharmaceutical Non-GAAP EPS of $101.90 beats by $102.90, revenue of $214M beats by $30.92M
Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline
Entropy Technologies LP Grows Position in Ultragenyx Pharmaceutical Inc. $RARE
Fifth Third Bancorp Acquires New Holdings in Ultragenyx Pharmaceutical Inc. $RARE
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
Ultragenyx outlines $730M-$760M 2026 revenue as it targets two gene therapy PDUFAs in August and September
Ultragenyx Pharmaceutical Q1 2026 Earnings Call Transcript
Ultragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates
Ultragenyx Pharmaceutical GAAP EPS of -$1.84 misses by $0.32, revenue of $136M misses by $22.41M
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
Earnings Scheduled For May 5, 2026
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Lags Revenue Estimates
Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – RARE
RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells $98,202.51 in Stock
Aberdeen Group plc Buys 496,295 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
ULTRAGENYX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – RARE
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE